Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however,
Artiva stopped making a medicine called AlloNK after safety problems happened. When a medicine has serious safety issues, it usually means the company must restart or stop its work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.